Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14,...
Hence then, the article about illimis therapeutics closes 58 billion krw 42 million series b financing to accelerate cns and immune disease drug development via gaia platform was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform )
Also on site :
- MI-W vs RCB-W Dream11 Prediction, Dream11 Playing XI, Today Match 1, WPL 2026
- Morton East student killed in shooting near Cicero school
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Varonis Systems, Inc. of Class Action Lawsuit and Upcoming Deadlines - VRNS